Fatty liver diseases, bile acids, and FXR

@inproceedings{Zhu2016FattyLD,
  title={Fatty liver diseases, bile acids, and FXR},
  author={Yan Zhu and Hongxia Liu and Min Zhang and Grace L. Guo},
  booktitle={Acta pharmaceutica Sinica. B},
  year={2016}
}
The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even to hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive with various genetic and environmental susceptibility… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

  • American journal of physiology. Gastrointestinal and liver physiology
  • 2014

Fibroblast growth factor 15 deficiency impairs liver regeneration in mice.

  • American journal of physiology. Gastrointestinal and liver physiology
  • 2014

Similar Papers

Loading similar papers…